Polypharmacy

Shift the unit of clinical attention from the single prescription to the whole regimen, sorting the combined risk of concurrent drugs into three channels — pharmacokinetic collisions, pharmacodynamic summation, and the prescribing cascade — under one appropriate-versus-problematic binary.

Core Idea

Polypharmacy is the phenomenon in which a patient takes multiple medications concurrently — often defined as five or more — so that the combined regimen generates risks not predictable from any single drug alone. It has three reinforcing components: pharmacokinetic interactions at shared elimination pathways, pharmacodynamic interactions summing at the effector level, and the self-amplifying prescribing cascade where one drug's side effect is misread and treated with another.

Scope of Application

Polypharmacy lives across the clinical-pharmacology subfields of medicine and health systems; its reach is bounded by a patient on a concurrent set of agents whose combination was never evaluated as a whole.

• Geriatric medicine — the home turf, where comorbidity-driven guideline pharmacotherapy assembles long regimens piecemeal.
• Clinical pharmacology — characterizing interactions and designing dosage adjustments across the regimen.
• Primary care and hospital medicine — medication reconciliation and deprescribing initiatives.
• Pharmacy practice — comprehensive medication review built on the appropriate-versus-problematic triage.
• Health-systems research — linking regimen length to falls, hospitalizations, and cognitive decline.
• Pharmacoeconomics — cost-effectiveness analysis of complex regimens and deprescribing.

Clarity

Naming polypharmacy makes legible a risk no single-drug assessment can see: a medication list can be hazardous even when every drug on it is correctly prescribed. It moves the unit of attention to the regimen as a whole and forces the decisive distinction between appropriate and problematic polypharmacy — same drug count, opposite meaning — separable only by asking whether each agent still has a current indication and whether the combination was ever reviewed as a unit.

Manages Complexity

A long list is intractable by brute force: the interaction space grows combinatorially. Polypharmacy tames it by relocating analysis to the whole regimen, then sorting the open-ended space into three mechanism-channels tracked separately — pharmacokinetic collisions at shared enzymes, pharmacodynamic summation at shared effectors, and the cascade loop. Over them sits one appropriateness binary, operationalized by Beers and STOPP/START, reducing a combinatorial audit to a small structured review.

Abstract Reasoning

Polypharmacy licenses a diagnostic move inferring regimen-level hazard invisible per-prescription, run through three channel-specific inferences. Its interventionist move is deprescribing — monitored subtraction predicted to remove risk without losing benefit for cascade-generated or indication-orphaned drugs. Its boundary-drawing move separates appropriate from problematic and PK from PD so the fix aims correctly, and it predicts the cascade lengthens regimens iteratively.

Knowledge Transfer

Within clinical pharmacology the construct transfers as mechanism, its channels, appropriateness binary, and deprescribing inverse porting across geriatrics, primary care, pharmacy, and health-systems research. Beyond medicine it is a shared abstract mechanism — many concurrent interventions accumulating disproportionate burden, seen in regulatory accretion and feature-creep — but what travels is a composition of parent primes (cumulative_burden_or_load, interaction, complexity, cascade), not the named clinical concept whose PK/PD substrate and risk lists stay home. dag_edges:

Relationships to Other Abstractions

Current abstraction Polypharmacy Domain-specific

Parents (5) — more general patterns this builds on

• Polypharmacy is part of, conditional Pharmacokinetic Interaction Domain-specific

  Polypharmacy conditionally contains Pharmacokinetic Interaction as the ADME- layer channel where one regimen member shifts another's exposure.

• Polypharmacy is part of, typical Pharmacological Interaction Domain-specific

  Pharmacological Interaction is a constitutive part of Polypharmacy.

• Polypharmacy is part of, conditional Therapeutic Duplication Domain-specific

  Polypharmacy conditionally contains Therapeutic Duplication when fragmented additions place multiple uncoordinated agents on one pharmacological target.

• Polypharmacy is part of, conditional Cascade Prime

  Polypharmacy conditionally contains a prescribing Cascade in which one drug's side effect is misread as disease and triggers another drug iteratively.

• Polypharmacy is a decomposition of Complexity Prime

  Removing clinical vocabulary leaves a multi-component system whose pairwise and higher-order interactions, feedback, and coordination cost grow faster than its apparent component count.

Hierarchy paths (82) — routes to 26 parentless roots

• Polypharmacy → Pharmacokinetic Interaction → Pharmacological Interaction → Synergy and Antagonism → Nonlinearity

Show alternative paths (81)

Neighborhood in Abstraction Space

Polypharmacy sits in a crowded region of the domain-specific corpus (36^th percentile for distinctiveness): several abstractions share nearly its structure, so a description that fits it tends to fit its neighbors too.

Family — Pharmacokinetics & Drug Response (19 abstractions)

Nearest neighbors

• Therapeutic Duplication — 0.89
• Pharmacokinetic Interaction — 0.85
• Adverse Drug Event — 0.85
• Pharmacodynamic Antagonism — 0.85
• Adverse Drug Reaction — 0.85

Computed from structural-signature embeddings · 2026-07-12